Harrow Health Inc SEC Filings

Harrow, Inc. (HROW) reported Q3 2025 results, showing strong top-line growth and a swing to profitability for the quarter while executing a major refinancing. Revenue rose to $71.6 million from $49.3 million a year ago, driven mainly by product sales of $71.5 million. Gross profit reached $53.9 million. Operating income was $14.7 million, and net income was $1.0 million (diluted EPS $0.03) versus a prior-year loss.

Year to date, Harrow recorded a net loss of $11.8 million, reflecting higher interest expense and a $7.8 million loss on extinguishment of debt tied to balance sheet changes. The company issued $250.0 million of 8.625% senior notes due 2030 and repaid its Oaktree Loan and 2026/2027 notes in September. Cash and cash equivalents were $74.3 million at quarter end, supported by $35.5 million net cash provided by operating activities for the first nine months of 2025. Shares outstanding were 37,037,453 as of November 10, 2025.

Harrow, Inc. (HROW) furnished materials announcing financial results for the period ended September 30, 2025 and recent corporate updates. The company provided a press release, a stockholder letter, and an investor presentation for reference.

These materials were furnished under Items 2.02 and 7.01 and are not deemed “filed” for liability purposes or incorporated by reference unless expressly stated. Exhibits include a press release, stockholder letter, and a corporate presentation.

Harrow, Inc. director/officer Francis William Mullery Jr. reported an initial beneficial ownership filing dated 10/06/2025. The filing discloses a stock option for 33,000 shares of common stock with an exercise price of $48.18. The option vests 25% after one year and the remainder in equal quarterly installments over the next three years, becoming fully vested and exercisable on 09/30/2029. The form was signed on 10/10/2025.

Harrow, Inc. submitted a Form 25 notification concerning removal of its registered class of securities from the Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934. The filing identifies the issuer's principal office in Nashville, Tennessee, and includes a contact telephone number. The document lists the standard regulatory rule checkboxes for striking a listing but does not indicate which specific rule provision was selected or provide an effective delisting date.

The filing states that Nasdaq certifies it has complied with exchange rules to strike the securities and that the issuer has complied with exchange requirements governing voluntary withdrawal, where applicable. Other than procedural certification and administrative details (including an OMB control number), the filing contains no financial results, transactions, or reasons for the removal.

Nasdaq Stock Market LLC has filed a Form 25 notification to remove the class of securities of Harrow, Inc. (HROW) from listing and/or registration on the Nasdaq exchange. The filing identifies the issuer and exchange and certifies Nasdaq believes it meets the requirements to submit this notice. The document does not include a signed signature block or detail which rule provision was checked for the removal.

Harrow, Inc. and certain subsidiaries entered into a new senior secured revolving credit agreement with Fifth Third Bank providing an initial facility of $40.0 million and an uncommitted incremental revolving line up to $20.0 million. The facility is secured and includes subsidiary guarantors, and it matures on September 26, 2030 or, if earlier, 91 days prior to the earliest maturity date of the company’s 8.625% senior notes due 2030. The credit line increases the company’s committed liquidity and provides flexibility through an additional uncommitted incremental option; the agreement names Fifth Third as administrative agent, letter of credit issuer, swing line lender, lead arranger and bookrunner.